Article Sidebar

PDF
Date Published: 13/02/2023
Abstract Views: 333
Views PDF: 170
DOI: https://doi.org/10.51298/vmj.v521i1.4019
Issue
Vol. 521 No. 1 (2022)
Section
Các bài báo
How to Cite
Lê, T. X. M., & Đỗ, T. T. O. (2023). CLINICAL, LABORATORY, MICRPBIOLOGICAL AND SHORT-TEM OUTCOMES OF COMMUNITY-ACQUIRED PNEUMONIA IN HOSPITALIZED COPD PATIENTS. Vietnam Medical Journal, 521(1). https://doi.org/10.51298/vmj.v521i1.4019

CLINICAL, LABORATORY, MICRPBIOLOGICAL AND SHORT-TEM OUTCOMES OF COMMUNITY-ACQUIRED PNEUMONIA IN HOSPITALIZED COPD PATIENTS

Thị Xuân Mai Lê1,, Thị Tường Oanh Đỗ2
1 People's Hospital 115
2 Pham Ngoc Thach University of Medicine

Main Article Content

Abstract

Objectives: To describes the prevalence and clinical, laboratory, microbiological and short-term outcomes of community-acquired pneumonia in hospitalized COPD patients, and also investigates risk factors for CAP in this group of patients. Subjects and methods: Cohort study on 180 COPD patients hospitalized for acute lower respiratory tract infections. Patients were divided into 2 groups of CAP-COPD (n=58) and EACOPD (n=122) based on new progressive infiltrates or consolidation on chest radiograph. Anthropometric, clinical, laboratory, and microbiological characteristics and course of hospital stay were all recorded. Results: The rate of CAP in hospitalized COPD patients was 32.2%. COPD patients with CAP had lower BMI, more severe obstruction (FEV1%), clinical manifestations (fever, purulent sputum, increased sputum volume) and paraclinical indicators (leukocytosis, decreased eosinophil, increased CRP, changes in arterial blood gas) more severe than exacerbation patients. The CAP group had a higher rate of respiratory failure and a longer hospital stay than the exacerbation group. Independent risk factors predicting CAP in patients with COPD include fever (OR=3.4451); FEV1<30% (OR=3,517); BC>10K/µL (OR=3.115), CRP (OR=1,061). The CRP cut-off was 15.745mg/l with AUC 0.912; sensitivity 93.1%; specificity 77%. Conclusion: COPD patients hospitalized for CAP have many differences in clinical, paraclinical and disease progression compared with COPD exacerbations and have independent risk factors predicting the occurrence of CAP in COPD patients.

Article Details

Keywords

COPD exacerbation, community-acquired pneumonia, pulmonary infiltration/ consolidation

References

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2020). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. https://goldcopd.org/wp-content/ /GOLD-2020- FINAL-ver1.2-03Dec19_WMV.pdf.
2. Metlay J, Waterer G, Long A, Anzueto A, Brozek J, Crothers K et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the ATS/IDSA. Am J Resp Critic Care Med. 2019;200(7):e45-e67
3. Sharafkhaneh A., Tavakoli-Tabasi S., Musher D. (2017). Mortality in Patients Admitted for Concurrent COPD Exacerbation and Pneumonia. COPD. 14(4), pp. 462.
4. Finney L.J., Padmanaban V., Todd S., et al (2019). Validity of the diagnosis of pneumonia in hospitalised patients with COPD, ERJ Open Res. 5(2).
5. Williams N.P., Coombs N.A., Johnson M.J., et al (2017). Seasonality, risk factors and burden of community-acquired pneumonia in COPD patients: a population database study using linked health care records. Int J Chron Obstruct Pulmon Dis. 12, pp. 313-322.
6. Huerta A., Crisafulli E., Menendez R., et al (2013). Pneumonic and nonpneumonic exacerbations of COPD: inflammatory response and clinical characteristics. Chest. 144(4), pp. 1134-1142.
7. Đặng Quỳnh Giao Vũ, Lê Thượng Vũ. (2017). Đặc điểm lâm sàng và kết cục của viêm phổi ở bệnh nhân bệnh phổi tắc nghẽn mạn tính. Tạp Chí Thời Sự Y Học 9, pp. 63-69
8. Martinez-Garcia M.A., Faner R., Oscullo G., et al (2020). Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis. Am J Respir Crit Care Med. 201(9), pp. 1078-1085.